|
|
Volumn 94, Issue 7, 2002, Pages 474-475
|
|
Upstaging tamoxifen? New classes of drugs emerging for breast cancer
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANASTROZOLE;
ANTIBIOTIC AGENT;
ANTIESTROGEN;
ANTINEOPLASTIC AGENT;
AROMATASE;
AROMATASE INHIBITOR;
CONTRACEPTIVE AGENT;
ESTROGEN;
ESTROGEN RECEPTOR;
EXEMESTANE;
FULVESTRANT;
PENICILLIN G;
PLACEBO;
RALOXIFENE;
SELECTIVE ESTROGEN RECEPTOR MODULATOR;
TAMOXIFEN;
BREAST CANCER;
BREAST METASTASIS;
CANCER HORMONE THERAPY;
CANCER INCIDENCE;
CANCER RECURRENCE;
CANCER RESEARCH;
CANCER RISK;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG CLASSIFICATION;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG RECEPTOR BINDING;
ENDOMETRIUM CANCER;
FEMALE;
HIGH RISK PATIENT;
HUMAN;
NOTE;
OSTEOPOROSIS;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
|
|
EID: 0037012336
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/94.7.474 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|